A bioelectric capsule tricks the brain into feeling full by activating the stomach’s stretch receptors.

This meta-analysis using individual patient data assesses which components of collaborative care are most effective in reducing symptoms of depression in primary care.

Past neuroscience and psychology studies have shown that after the human brain encodes specific events or information, it can periodically reactivate them to facilitate their retention, via a process known as memory consolidation. The reactivation of memories has been specifically studied in the context of sleep or rest, with findings suggesting that during periods of inactivity, the brain reactivates specific memories, allowing people to remember them in the long term.

Researchers at the University of Pennsylvania and other institutions in the United States recently conducted a study exploring the possibility that the brain engages in a similar reactivation process during wakefulness to store important information for shorter periods of time. Their findings, published in Nature Neuroscience, suggest that the spontaneous reactivation of specific stimuli in the brain during the brief intervals between their encoding predicts the accuracy with which people remember them at the end of a memory task.

“Mike Kahana and I were both quite interested in the long history of thinking about rehearsal and its effects on the way in which people later recalled things,” Dr. David Halpern, the first author of the paper, told Medical Xpress. “Rehearsal is challenging to study since people often do it without any overt behavior (unless we ask them to rehearse out loud).”

While researchers continue to work on a full cure for Alzheimer’s disease, they’re finding treatments that can help manage symptoms and delay their onset, including the recently approved next-gen therapies lecanemab and donanemab.

Both treatments have been approved by US regulators in the last couple of years, and they work by clearing out some of the amyloid protein plaques in the brain that are linked to Alzheimer’s. However, there’s some debate over how effective they are.

To quantify the effectiveness of lecanemab and donanemab in more meaningful terms, researchers from the Washington University School of Medicine (WashU Medicine) recruited 282 volunteers with Alzheimer’s, analyzing the impacts of taking these drugs over an average of nearly three years.

New analysis recasts benefits of treatment in relation to day-to-day impacts on patients’ lives

To buffer the brain against menaces in the blood, a dynamic, multi-tiered system of protection is built into the brain’s blood vessels.

An experimental drug appears to reduce the risk of Alzheimer’s-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a study led by the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), which is based at Washington University School of Medicine in St. Louis.

The findings suggest—for the first time in a clinical trial—that early treatment to remove amyloid plaques from the brain many years before symptoms arise can delay the onset of Alzheimer’s dementia.

The study is published in The Lancet Neurology.